The simple test that will diagnose Alzheimer’s within days – available next year

Blood tests for Alzheimer’s disease will be rolled out as part of routine NHS care at a number of hospitals from early next year, The i Paper can reveal.

The tests will cut the time taken to be diagnosed with dementia from years to as little as days after a first visit to a memory clinic, allowing faster access to drug treatments and entry to clinical trials.

Diagnosis currently takes months to years because it requires several hospital appointments, including for brain scans and painful lumbar puncture tests – which have long waiting lists.

Blood tests for diagnosing dementia could “absolutely revolutionise the way dementia is diagnosed”, Alzheimer’s Society research director Fiona Carragher has said.

Hospitals leapfrogging trial results

The blood tests are currently being investigated in two large trials to see how they fit into NHS services, due to complete in 2029.

But, as the tests have been proven to work, some hospitals are already offering them as part of routine care, without waiting for the trials to finish, and the number that will do so is set to rise next year.

At the moment, University College Hospital, London, is the only British hospital to do so, and a few other university-linked hospitals have started sending it blood samples, said Dr Ashvini Keshavan, a neurologist there.

Now, more hospitals are going to start doing the tests themselves, which will widen access, said Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society. NHS hospitals have the authority to introduce tests into routine care ahead of trial results.

“We’re beginning to have conversations [where] some trusts are saying they will fund the use of blood tests in their dementia pathway in order to start collecting real world data now,” Oakley said. “We thought it’d take longer than this.”

Manchester Brain Health Centre, part of Manchester Royal Infirmary, will start offering the tests in “a few weeks”, said its dementia research lead, Dr Ross Dunne.

The i Paper has been unable to identify the hospitals planning to offer these tests next year. There is no central register showing which hospitals currently offer the service, and Oakley declined to reveal which hospitals will be first to do so.

Proteins in the blood

Alzheimer’s disease, the most common type of dementia, is caused by a build-up of toxic proteins in the brain, called amyloid and tau. The blood test measures a form of tau protein called ptau217, which are higher if someone has more brain tau and amyloid.

The test will also help doctors narrow down which subtype of the condition patients have. High blood tau makes an Alzheimer’s diagnosis more likely. Low blood tau levels could point to vascular dementia, caused by strokes or damage to blood vessels, which starve brain cells of oxygen and nutrients. Other types are Lewy body dementia – linked with movement problems similar to Parkinson’s disease – frontotemporal dementia, and mixed dementia.

A faster, confirmed diagnosis should reduce anxiety and stress for people who suspect they are developing memory problems, and their families, said Oakley.

According to Alzheimer’s Society surveys, people who get a diagnosis find it helpful for making plans. “It enabled them to know what to expect going forward, and to get a power of attorney in place,” said Oakley.

“It meant that their loved one could play a role in picking the care home, and then they could go on that last holiday independently, or retire early.”

For the trusts introducing the blood test, it will be given at hospital memory clinics or neurology departments, after a clinical and cognitive assessment.

If a patient is not being seen at one of the participating hospitals, they may have no way to access the test other than paying for it privately – creating a possible postcode lottery.

Doctors have also warned that paying for private blood tests outside of a memory clinic could lead to false positives, creating more harm than good.

Early entry to clinical trials

Knowing the type of dementia means someone may be able to have drug treatments or enter clinical trials, especially those in the earlier stages of the condition, said Dunne.

“Those people tend to really want to know: number one, is this more than ageing? And if it is, what is it? And because they’re pretty early on, they also are keen to get into a clinical trial, if one is available.”

If someone has Alzheimer’s, they may be offered tablets that can slightly reduce the memory and concentration problems. Other drugs given by infusion that are designed to slow disease progression may also be available in future.

The infusions were turned down for NHS use, but that decision is under review, after cost criteria were loosened as part of a recent UK-US drug trade deal.

The test would also help rule out Alzheimer’s in those who have memory and concentration problems caused by depression or obstructive sleep apnoea, said Professor Charles Marshall, a neurologist at Queen Mary University of London.

“There are lots of other things that aren’t dementia that can affect your memory,” he said.

“If we can detect a specific disease process happening in the brain, then we can hopefully know at an earlier stage whether this is something that might stay the same, or even be treatable and improve.”

Original source The simple test that will diagnose Alzheimer’s within days – available next year

Back to home